HSP90AA1 and pulmonary arterial hypertension: A study in a monocrotaline-induced rat model of PH found that the use of HSP90 inhibitors alleviated the progression of PAH, manifested by decreased pulmonary arterial pressure and loss of right ventricular hypertrophy [74].